Loading...
For patients who undergo percutaneous coronary intervention (PCI) for coronary artery disease, the choice of antiplatelet agent for secondary prevention of cardiovascular ischemic events after a period of dual antiplatelet therapy (DAPT) remains uncertain. To strengthen the available evidence, researchers performed a meta-analysis using individual participant data from five randomized trials of P2Y12 inhibitors (ticagrelor or clopidogrel) versus aspirin monotherapy. Patients had received DAPT for a median duration of 12 months after PCI.
During a median follow-up of ≈3.5 years among more than 16,000 patients, treatment with P2Y12 inhibitors was associated with significantly reduced risk for major adverse cardiac and cerebrovascular events co…